Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, reported today that it has issued inducement awards to two new non-executive employees.The awards were made on April 1, 2014 under Zogenix’s Employment Inducement Equity Incentive Award Plan, which provides for the granting of equity awards to new employees of Zogenix. The inducement awards consist of options to purchase an aggregate of 16,000 shares of Zogenix common stock. The options have a ten-year term and an exercise price equal to $2.89, the fair market value of Zogenix common stock on the date of grant. The options vest over a four-year period, with 25% of the options vesting on the first anniversary of the date of hire and the remainder vesting in equal monthly installments over the three years thereafter. Zogenix, Inc. (NASDAQ:ZGNX) shares after opening at $2.83 moved to $2.87 on last trade day and at the end of the day closed at $2.58. Company price to sales ratio in past twelve months was calculated as 10.91 and price to cash ratio as 5.00. Zogenix, Inc. (NASDAQ:ZGNX) showed a negative weekly performance of -5.49%.
Alimera Sciences Inc (NASDAQ:ALIM) a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has resubmitted its New Drug Application for ILUVIEN® to the U.S. Food and Drug Administration (FDA). At this time, Alimera awaits the FDA’s acceptance of the resubmission and a Prescription Drug User Fee Act (PDUFA) date. Alimera intends to provide that information when it becomes available. Alimera Sciences Inc (NASDAQ:ALIM) shares fell -9.16% in last trading session and ended the day on $6.74. ALIM return on equity ratio is recorded as 296.40% and its return on assets is -198.80%. Alimera Sciences Inc (NASDAQ:ALIM) yearly performance is 127.70%.
KYTHERA Biopharmaceuticals (NASDAQ:KYTH) CEO Keith Leonard unloaded 13,260 shares of KYTHERA Biopharmaceuticals stock on the open market in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $39.08, for a total value of $518,200.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) shares moved down -5.95% in last trading session and was closed at $35.90, while trading in range of $34.40-$38.96.Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) year to date performance is -3.88%.
Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) announced additional Phase 3 data supporting the efficacy and safety of EXPAREL® (bupivacaine liposome injectable suspension) to achieve a femoral nerve block in patients undergoing total knee arthroplasty. The Company previously announced results of the primary efficacy endpoint, a statistically significant reduction in cumulative pain scores over 72 hours compared to placebo (P<0.0001). Secondary endpoints presented at the 39th Annual Meeting of the American Society of Regional Anesthesia and Pain Medicine (ASRA) found that a higher percentage of patients who received EXPAREL were pain-free, consumed fewer opioids and reported higher satisfaction with their pain control. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) weekly performance is %. On last trading day company shares ended up $64.38. Pacira Pharmaceuticals Inc (NASDAQ:PCRX) distance from 50-day simple moving average is -7.71%. Analysts mean target price for the company is $86.07.
Leave a Reply